Cost-Effectiveness of Nusinersen and Universal Newborn Screening for Spinal Muscular Atrophy
Authors:
- 11 July 2020
- journal article
- research article
- Published by Elsevier in The Journal of Pediatrics
- Vol. 227, 274-280.e2
Abstract
No abstract availableKeywords
Funding Information
- National Human Genome Research Institute
This publication has 42 references indexed in Scilit:
- Nusinersen treatment of spinal muscular atrophy: current knowledge and existing gapsDevelopmental Medicine & Child Neurology, 2018
- Single-Dose Gene-Replacement Therapy for Spinal Muscular AtrophyNew England Journal of Medicine, 2017
- Nusinersen versus Sham Control in Infantile-Onset Spinal Muscular AtrophyNew England Journal of Medicine, 2017
- 209th ENMC International Workshop: Outcome Measures and Clinical Trial Readiness in Spinal Muscular Atrophy 7–9 November 2014, Heemskerk, The NetherlandsNeuromuscular Disorders, 2015
- Spinal Muscular AtrophiesPediatric Clinics of North America, 2015
- Observational study of spinal muscular atrophy type I and implications for clinical trialsNeurology, 2014
- Pan-ethnic carrier screening and prenatal diagnosis for spinal muscular atrophy: clinical laboratory analysis of >72 400 specimensEuropean Journal of Human Genetics, 2011
- Carrier screening for spinal muscular atrophyGenetics in Medicine, 2008
- Spinal muscular atrophyThe Lancet, 2008
- Spinal Muscular Atrophy: Survival Pattern and Functional StatusPediatrics, 2004